Immunocore/$IMCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunocore
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Ticker
$IMCR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
493
ISIN
US45258D1054
Website
Immunocore Metrics
BasicAdvanced
$1.9B
-
-$0.43
0.75
-
Price and volume
Market cap
$1.9B
Beta
0.75
52-week high
$48.50
52-week low
$23.15
Average daily volume
389K
Financial strength
Current ratio
6.36
Quick ratio
6.034
Long term debt to equity
114.215
Total debt to equity
114.668
Interest coverage (TTM)
-1.59%
Management effectiveness
Return on assets (TTM)
-1.83%
Return on equity (TTM)
-5.86%
Valuation
Price to revenue (TTM)
5.798
Price to book
5.12
Price to tangible book (TTM)
5.12
Price to free cash flow (TTM)
75.519
Growth
Revenue change (TTM)
25.75%
Earnings per share change (TTM)
-64.64%
3-year revenue growth (CAGR)
85.08%
3-year earnings per share growth (CAGR)
-50.18%
What the Analysts think about Immunocore
Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Immunocore Financial Performance
Revenues and expenses
Immunocore Earnings Performance
Company profitability
Immunocore News
AllArticlesVideos
Immunocore to present at upcoming investor conferences
GlobeNewsWire·2 months ago
Insiders Make Huge Purchases of These 4 Biotech Stocks
24/7 Wall Street·2 months ago
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunocore stock?
Immunocore (IMCR) has a market cap of $1.9B as of June 03, 2025.
What is the P/E ratio for Immunocore stock?
The price to earnings (P/E) ratio for Immunocore (IMCR) stock is 0 as of June 03, 2025.
Does Immunocore stock pay dividends?
No, Immunocore (IMCR) stock does not pay dividends to its shareholders as of June 03, 2025.
When is the next Immunocore dividend payment date?
Immunocore (IMCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunocore?
Immunocore (IMCR) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.